Jesse’s Journey is pleased to provide the latest update from Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. regarding the completion of the 48-week VISION-DMD study:
The 48-week top-line data readout for vamorolone shows that the statistically robust efficacy demonstrated at 24-weeks is maintained across multiple efficacy endpoints at 48 weeks. In addition, vamorolone treatment at both doses (2 and 6 mg/kg/day) reversed the growth impairment observed during prednisone treatment and were associated with fewer adverse events, including those associated with corticosteroid use.
Jesse’s Journey has granted $1 million to support a clinical trial of vamorolone in Canada and is expected to enrol the first patients early in 2022.
Click here to read Santhera’s latest letter for the Duchenne community:
Click here to read the full press release: